Literature DB >> 18971955

Determinants of variation in human serum paraoxonase activity.

D L Rainwater1, S Rutherford, T D Dyer, E D Rainwater, S A Cole, J L Vandeberg, L Almasy, J Blangero, J W Maccluer, M C Mahaney.   

Abstract

Paraoxonase-1 (PON1) is associated with high-density lipoprotein (HDL) particles and is believed to contribute to antiatherogenic properties of HDLs. We assessed the determinants of PON1 activity variation using different substrates of the enzyme. PON1 activity in serum samples from 922 participants in the San Antonio Family Heart Study was assayed using a reliable microplate format with three substrates: paraoxon, phenyl acetate and the lactone dihydrocoumarin. There were major differences among results from the three substrates in degree of effect by various environmental and genetic factors, suggesting that knowledge of one substrate activity alone may not provide a complete sense of PON1 metabolism. Three significant demographic covariates (age, smoking status and contraceptive usage) together explained 1-6% of phenotypic variance, whereas four metabolic covariates representing lipoprotein metabolism (apoAII, apoAI, triglycerides and non-HDL cholesterol) explained 4-19%. Genes explained 65-92% of phenotypic variance and the dominant genetic effect was exerted by a locus mapping at or near the protein structural locus (PON1) on chromosome 7. Additional genes influencing PON1 activity were localized to chromosomes 3 and 14. Our study identified environmental and genetic determinants of PON1 activity that accounted for 88-97% of total phenotypic variance, suggesting that few, if any, major biological determinants are unrepresented in the models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971955      PMCID: PMC2643132          DOI: 10.1038/hdy.2008.110

Source DB:  PubMed          Journal:  Heredity (Edinb)        ISSN: 0018-067X            Impact factor:   3.821


  42 in total

1.  Large upward bias in estimation of locus-specific effects from genomewide scans.

Authors:  H H Göring; J D Terwilliger; J Blangero
Journal:  Am J Hum Genet       Date:  2001-10-09       Impact factor: 11.025

2.  Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.

Authors:  D I Draganov; P L Stetson; C E Watson; S S Billecke; B N La Du
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

3.  A high-resolution recombination map of the human genome.

Authors:  Augustine Kong; Daniel F Gudbjartsson; Jesus Sainz; Gudrun M Jonsdottir; Sigurjon A Gudjonsson; Bjorgvin Richardsson; Sigrun Sigurdardottir; John Barnard; Bjorn Hallbeck; Gisli Masson; Adam Shlien; Stefan T Palsson; Michael L Frigge; Thorgeir E Thorgeirsson; Jeffrey R Gulcher; Kari Stefansson
Journal:  Nat Genet       Date:  2002-06-10       Impact factor: 38.330

Review 4.  Novel family-based approaches to genetic risk in thrombosis.

Authors:  J Blangero; J T Williams; L Almasy
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

5.  A quantitative trait locus influences coordinated variation in measures of ApoB-containing lipoproteins.

Authors:  David L Rainwater; Michael C Mahaney; John L VandeBerg; Gerome Brush; Laura Almasy; John Blangero; Bennett Dyke; James E Hixson; Shelley A Cole; Jean W MacCluer
Journal:  Atherosclerosis       Date:  2004-10       Impact factor: 5.162

6.  Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins.

Authors:  D L Rainwater; P H Moore; W R Shelledy; T D Dyer; S H Slifer
Journal:  J Lipid Res       Date:  1997-06       Impact factor: 5.922

7.  Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids.

Authors:  S T Reddy; D J Wadleigh; V Grijalva; C Ng; S Hama; A Gangopadhyay; D M Shih; A J Lusis; M Navab; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

8.  Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Authors:  Vicent Ribas; José Luis Sánchez-Quesada; Rosa Antón; Mercedes Camacho; Josep Julve; Joan Carles Escolà-Gil; Luís Vila; Jordi Ordóñez-Llanos; Francisco Blanco-Vaca
Journal:  Circ Res       Date:  2004-09-23       Impact factor: 17.367

Review 9.  Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Authors:  Hong-Liang Li; De-Pei Liu; Chih-Chuan Liang
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

10.  Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status.

Authors:  Gail P Jarvik; Rachel Jampsa; Rebecca J Richter; Chris S Carlson; Mark J Rieder; Deborah A Nickerson; Clement E Furlong
Journal:  Pharmacogenetics       Date:  2003-05
View more
  27 in total

1.  Methylmercury exposure, PON1 gene variants and serum paraoxonase activity in Eastern James Bay Cree adults.

Authors:  Olivia Drescher; Eric Dewailly; Caroline Diorio; Nathalie Ouellet; Elhadji Anassour Laouan Sidi; Belkacem Abdous; Beatriz Valera; Pierre Ayotte
Journal:  J Expo Sci Environ Epidemiol       Date:  2014-01-22       Impact factor: 5.563

2.  R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke.

Authors:  Abdolkarim Mahrooz; Ghorban Gohari; Mohammad-Bagher Hashemi; Mehryar Zargari; Hadis Musavi; Mahmoud Abedini; Ahad Alizadeh
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

Review 3.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

4.  Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Authors:  Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

5.  The Q192R polymorphism of the paraoxonase 1 gene is a risk factor for coronary artery disease in Saudi subjects.

Authors:  Mohammed A Hassan; Omar S Al-Attas; Tajamul Hussain; Nasser M Al-Daghri; Majed S Alokail; Abdul K Mohammed; Benjamin Vinodson
Journal:  Mol Cell Biochem       Date:  2013-04-27       Impact factor: 3.396

6.  Effects of PON polymorphisms and haplotypes on molecular phenotype in Mexican-American mothers and children.

Authors:  Karen Huen; Lisa Barcellos; Kenneth Beckman; Sherri Rose; Brenda Eskenazi; Nina Holland
Journal:  Environ Mol Mutagen       Date:  2011-03       Impact factor: 3.216

7.  Localization of multiple pleiotropic genes for lipoprotein metabolism in baboons.

Authors:  David L Rainwater; Laura A Cox; Jeffrey Rogers; John L VandeBerg; Michael C Mahaney
Journal:  J Lipid Res       Date:  2009-03-08       Impact factor: 5.922

8.  Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes.

Authors:  Karen Huen; Kim Harley; Asa Bradman; Brenda Eskenazi; Nina Holland
Journal:  Toxicol Appl Pharmacol       Date:  2010-01-04       Impact factor: 4.219

Review 9.  Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis.

Authors:  Issa J Dahabreh; Georgios D Kitsios; David M Kent; Thomas A Trikalinos
Journal:  Genet Med       Date:  2010-10       Impact factor: 8.822

10.  Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms.

Authors:  Karen Huen; Kim Harley; Jordan Brooks; Alan Hubbard; Asa Bradman; Brenda Eskenazi; Nina Holland
Journal:  Environ Health Perspect       Date:  2009-06-09       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.